Biotech Values

[Mpower]

Thanks for the feedback.

Harry Hixson, the acting (interim) CEO was the chairman of the board when the debacle befell SQNM. He took over after the company ousted some key executive leadership. That being said, his credentials are quite impressive -- he was the former Chairman & Chief Executive Officer of Amgen.

One important consideration in speculating about what exactly transpired at SQNM ahead of the debacle was taking note of the massive short position that had been building. This short position was huge and built in the face of the data that turned out to be "mishandled." Would it be too much of a stretch to imagine a few key employees "coming clean" to management about inadequate policies & procedures one month before DS commercialization (i.e. compromising the integrity of the test data), thus de-railing the launch and throwing the co. and stock price into a near death spiral.